Charles M Balch, Ning Liao, Dennis S C Lam, Jeffrey N Weitzel, et al. ecancer 2026, 20:2071
Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimizing treatments based on individual genetic profiles. Cancer prevention represents not merely a health opportunity but an economic imperative.
16 Mar, 2026